drugset
drugset / Trial / NCT00217412

Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia

NCT00217412 ↗

Phase 1 Completed 60 enrolled National Cancer Institute (NCI)
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This phase I trial is studying the side effects and best dose of vorinostat when given together with isotretinoin in treating young patients with recurrent or refractory solid tumors, lymphoma, or leukemia. Drugs used in chemotherapy, such as vorinostat, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Vorinostat may also stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. Isotretinoin may cause cancer cells to look more like normal cells, and to grow and spread more slowly. Giving vorinostat together with isotretinoin may be an effective treatment for cancer.

Timeline

Start
2005-08
Primary completion
2009-09
Completion
2009-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Isotretinoin Other / unclassified — Oral
Subject Vorinostat Small molecule — Oral

Indications

Burkitt lymphoma Hodgkins lymphoma acute promyelocytic leukemia atypical teratoid rhabdoid tumor childhood acute lymphoblastic leukemia childhood acute myeloid leukemia childhood medulloblastoma chronic myeloid leukemia grade III lymphomatoid granulomatosis juvenile myelomonocytic leukemia large-cell immunoblastic lymphoma neuroblastoma supratentorial primitive neuroectodermal tumor